Aprogen Biologics Inc. (KRX:003060)
653.00
-5.00 (-0.76%)
At close: Sep 12, 2025
Aprogen Biologics Revenue
Aprogen Biologics had revenue of 14.90B KRW in the quarter ending June 30, 2025, a decrease of -1.94%. This brings the company's revenue in the last twelve months to 68.32B, down -7.21% year-over-year. In the year 2024, Aprogen Biologics had annual revenue of 67.38B, down -22.88%.
Revenue (ttm)
68.32B
Revenue Growth
-7.21%
P/S Ratio
1.89
Revenue / Employee
174.74M
Employees
391
Market Cap
128.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
Dec 31, 2020 | 53.32B | 2.42B | 4.75% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |